Markers indicating an activated immune microenvironment, such as higher tumor-infiltrating lymphocytes (TILs) [24–26] or higher expression of immune gene signatures, are associated with higher pCR rates [19, 27] and better long-term outcomes in HER2-positive BC [23, 28]. The gene discussed is ERBB2; the disease is neoplasm.